Navigation Links
Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer
Date:9/13/2012

NANJING, China, Sept. 13, 2012 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced the appointment of Mr. Hongquan Liu, as its Chief Executive Officer and Executive Director of the Board, effective October  8, 2012. Mr. Jinsheng Ren will continue to serve as Chairman of Simcere.

The Company also announced that Dr. Yehong Zhang, who currently serves as President of Simcere, will serve as Chief Executive Officer of Simcere MSD (Shanghai) Pharmaceutical Co. Ltd, the newly established joint venture between Simcere and Merck & Co., Inc. (NYSE: MRK), effective from October 8, 2012. Dr. Zhang will no longer hold the position of President of Simcere.  

Between 2000 and 2012, Mr. Hongquan Liu held the positions of Director and General Manager of Sino-Swed Pharmaceutical Corp. Ltd, the first pharmaceutical joint venture between China and Sweden. Prior to this, Mr. Liu held the positions of Chief Financial Officer and Chief Marketing and Business Officer of Pharmacia & Upjohn (China) Ltd., and General Manager of Pharmacia Corporation. Mr. Liu received an EMBA degree from China Europe International Business School (CEIBS) and a bachelor's degree from Shanxi College of Finance and Economics.

"I am delighted to welcome Hongquan to Simcere's management team," said Mr. Jinsheng Ren, Chairman of Simcere. "With nearly 30 years of management experience in the pharmaceutical industry, and as an Independent Director of Simcere for the last nine years, I am confident that as CEO, Hongquan will be instrumental in helping position Simcere for long-term sustainable growth.  With Hongquan leading the company's overall management and operations, I look forward to devoting more of my time to focusing on Simcere's mid- to long-term strategic direction and to building relationships with major stakeholders."

"I am very excited to join Simcere as Chief Executive Officer," said Mr. Liu. "With its abundant range of competitive products and solid management foundation, I am confident that Simcere has a promising future with high growth potential in China's rapidly developing pharmaceutical industry. I look forward to working alongside Mr. Ren and the entire management team to raise the quality of the company's operations and to strengthen its market competitiveness."

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:

Email: ir@simcere.com

 


In the United States:

Jie Liu D'Elia

Vice President

Simcere Pharmaceutical Group

Tel: +1-425-985-5530

 

In Beijing:

Yue Yu

Brunswick Group

Tel: +86-10-5960-8600

In the United States:

Cindy Zheng

Brunswick Group LLC

Tel: +1-212-333-3810

 

 

In Hong Kong:

Joseph Lo Chi-Lun

Brunswick Group

Tel: +852-3512-5000 


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2012 Results
2. Simcere Pharmaceutical Group to Announce Second Quarter 2012 Financial Results on Friday, August 10, 2012
3. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
4. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
5. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
6. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
7. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
8. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
9. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
10. Chester County Biopharmaceutical Firm to Expand, Create 151 New Jobs
11. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Worldwide ... achieve significant growth as next generation systems provide ... use radiology for cancer surgery. New systems pinpoint ... overdosing that has been such a problem previously, ... delivered. Radiosurgery robots take cancer surgery far beyond ...
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... and competitive market to drive long-term market growth ... very common set of chronic disorders that affect ... disparate in terms of their symptoms and key ... by dysregulation of immune pathways and an inappropriate ...
Breaking Medicine Technology:
(Date:2/5/2016)... New York (PRWEB) , ... February 05, 2016 , ... ... use and find themselves having to wait longer to access the treadmills. It’s a ... New Year’s resolutions to lose weight and get in shape by joining gyms, starting ...
(Date:2/5/2016)... ... , ... At its annual meeting held last week, the American Parkinson Disease ... of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We are pleased ... APDA President and CEO. “Pat has tirelessly served APDA since 2001 when he was ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Colorize ... on one drop zone to the next using Colorize's dynamic moving camera. Colorize is ... This package includes a 3D slideshow environment with 1 to 5 focus points per ...
(Date:2/5/2016)... ... 05, 2016 , ... On June 9-10, Las Vegas will ... education (CME) event presented by the Association for Comprehensive Care in Rare Diseases ... whose mission is to provide education, tools, and resources to primary care clinicians ...
(Date:2/5/2016)... Luis Obispo, CA (PRWEB) , ... February 05, 2016 , ... ... new changes that Medicare San Luis Obispo users can expect to see in 2016. ... , The two most significant changes will directly impact many San Luis Obispo seniors ...
Breaking Medicine News(10 mins):